Zenas BioPharma Files 8-K Report

Ticker: ZBIO · Form: 8-K · Filed: Jun 4, 2025 · CIK: 1953926

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

TL;DR

Zenas BioPharma filed an 8-K, likely with updates for investors.

AI Summary

On June 4, 2025, Zenas BioPharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Zenas BioPharma is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific financial or operational details that would indicate high risk.

Key Players & Entities

FAQ

What specific information is being disclosed in this 8-K filing?

The filing indicates it is for Regulation FD Disclosure and Financial Statements and Exhibits, but the specific details of the disclosure are not provided in the excerpt.

When was this 8-K report filed?

The report was filed on June 4, 2025.

What is the Commission File Number for Zenas BioPharma, Inc.?

The Commission File Number is 001-42270.

Where are Zenas BioPharma, Inc.'s principal executive offices located?

The principal executive offices are located at 852 Winter Street, Suite 250, Waltham, MA 02451.

What is the primary business of Zenas BioPharma, Inc. according to the filing?

The Standard Industrial Classification code indicates the company is in 'PHARMACEUTICAL PREPARATIONS [2834]'.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding Zenas BioPharma, Inc. (ZBIO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing